Filtered By:
Specialty: Cardiology
Drug: Vytorin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 100 results found since Jan 2013.
Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial
CONCLUSIONS: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:36154103 | DOI:10.1161/STROKEAHA.122.039728
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Philippa C Lavall ée Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL & lt;70 mg/dL After a Stroke
CONCLUSIONS: In this post hoc analysis of the TST trial, targeting an LDL cholesterol of <70 mg/dL reduced the risk of primary outcome compared with 100±10 mg/dL provided LDL cholesterol reduction from baseline was superior to 50%, thereby suggesting that the magnitude of LDL cholesterol reduction was as important to consider as the target level to achieve.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875; https://clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:37376989 | DOI:10.1161/STROKEAHA.123.042621
Source: Atherosclerosis - June 28, 2023 Category: Cardiology Authors: Pierre Amarenco Philippa C Lavall ée Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT.
Conclusions -The addition of ezetimibe to simvastatin in patients stabilized after ACS reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT00202878.
PMID: 28972004 [PubMed - as supplied by publisher]
Source: Circulation - September 30, 2017 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf FJ, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E Tags: Circulation Source Type: research
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials
CONCLUSIONS AND RELEVANCE: This study suggests that the benefits and risks of more intensive LDL-C-lowering statin-based therapies for recurrent stroke risk reduction might be more favorable than the benefits and risks of less intensive LDL-C-lowering statin-based therapies, especially for patients with evidence of atherosclerosis.PMID:35188949 | DOI:10.1001/jamaneurol.2021.5578
Source: Atherosclerosis - February 21, 2022 Category: Cardiology Authors: Meng Lee Chun-Yu Cheng Yi-Ling Wu Jiann-Der Lee Chia-Yu Hsu Bruce Ovbiagele Source Type: research
Lipid-Modifying Therapies and Stroke Prevention
Curr Neurol Neurosci Rep. 2022 May 13. doi: 10.1007/s11910-022-01197-4. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: We reviewed lipid-modifying therapies and the risk of stroke and other cerebrovascular outcomes, with a focus on newer therapies.RECENT FINDINGS: Statins and ezetimibe reduce ischemic stroke risk without increasing hemorrhagic stroke risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors similarly reduce ischemic stroke risk in statin-treated patients with atherosclerosis without increasing hemorrhagic stroke, even with very low achieved low-density lipoprotein cholesterol levels. Icosape...
Source: Atherosclerosis - May 13, 2022 Category: Cardiology Authors: Daniel G Hackam Robert A Hegele Source Type: research
Management of Hyperlipidemia After Stroke
AbstractPurpose of reviewHyperlipidemia is a key therapeutic target for stroke risk modification. The goal of this review is to highlight available treatment options and review their efficacy in the setting of general cardiovascular disease and after most subtypes of ischemic stroke and hemorrhagic stroke.Recent findingsStatins remain first-line in the management of hyperlipidemia to prevent stroke. In recent trials of patients with pre-existing atherosclerotic vascular disease, new agents, most notably PCSK9 inhibitors and ezetimibe, added additional stroke risk reduction when combined with statins.SummaryRisk of stroke c...
Source: Current Treatment Options in Cardiovascular Medicine - December 15, 2019 Category: Cardiology Source Type: research
Carotid Atherosclerosis Evolution when Targeting a Low-Density Lipoprotein Cholesterol Concentration < 70 mg/dL after an Ischemic Stroke of Atherosclerotic Origin.
Conclusions: In patients with ischemic stroke and atherosclerosis, an LDL-C target of <70 mg/dL (1.8 mmol/L) did not reduce the incidence of new carotid plaques but produced significantly greater regression of carotid atherosclerosis than an LDL-C target of 90 to 110 mg/dL. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01252875.
PMID: 32594766 [PubMed - as supplied by publisher]
Source: Circulation - June 28, 2020 Category: Cardiology Authors: Amarenco P, Hobeanu C, Labreuche J, Charles H, Giroud M, Meseguer E, Lavallée PC, Steg PG, Vicaut É, Bruckert E, Touboul PJ Tags: Circulation Source Type: research
Intracranial Hemorrhage in the TST Trial
CONCLUSIONS: Targeting an LDL cholesterol of <70 mg/dL compared with 100±10 mg/dL in patients with atherosclerotic ischemic stroke nonsignificantly increased the risk of ICH. Incident ICHs were not associated with low LDL cholesterol. Uncontrolled hypertension and anticoagulant therapy were associated with ICH which has important clinical implications.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01252875; EUDRACT identifier: 2009-A01280-57.PMID:34963300 | DOI:10.1161/STROKEAHA.121.035846
Source: Atherosclerosis - December 29, 2021 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Philippa C Lavall ée Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient ischemic attacks
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(6):36-43. doi: 10.17116/jnevro202312306136.ABSTRACTHigh and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary preventi...
Source: Atherosclerosis - June 29, 2023 Category: Cardiology Authors: A A Kulesh S N Yanishevskiy D A Demin L I Syromyatnikova O I Vinogradov Source Type: research
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891625 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E Tags: Circulation Source Type: research
Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891624 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Koh KK Tags: Circulation Source Type: research
Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891623 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Cordero A, Bertomeu-González V, Rodriguez-Mañero M Tags: Circulation Source Type: research
Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891622 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Thomopoulos C, Michalopoulou H Tags: Circulation Source Type: research
